Cargando…
The antibody response of haematological malignancies to COVID-19 infection and vaccination
Cancer patients with COVID-19 have reduced survival. While most cancer patients, like the general population, have an almost 100% rate of seroconversion after COVID-19 infection or vaccination, patients with haematological malignancies have lower seroconversion rates and are far less likely to gain...
Autor principal: | Seebacher, Nicole A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751459/ https://www.ncbi.nlm.nih.gov/pubmed/35017657 http://dx.doi.org/10.1038/s41416-021-01682-6 |
Ejemplares similares
-
COVID-19 vaccines for patients with haematological conditions
por: Sun, Clare, et al.
Publicado: (2021) -
Blunted humoral response after mRNA vaccine in patients with haematological malignancies
por: Kamboj, Mini
Publicado: (2021) -
COVID-19 and haematological malignancy: navigating a narrow strait
por: Rubinstein, Samuel M, et al.
Publicado: (2020) -
Strategic plan for management of COVID-19 in paediatric haematology and oncology departments
por: He, Yulei, et al.
Publicado: (2020) -
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria
por: Pike, Alexandra, et al.
Publicado: (2022)